DAR-901

BIOLOGICAL2 trials

Sponsors

Dartmouth-Hitchcock Medical Center

Conditions

Tuberculosis

Phase 1

Phase I Trial of DAR-901

CompletedNCT02063555

Dartmouth-Hitchcock Medical CenterTuberculosis

Start: 2014-02-28End: 2016-06-30Updated: 2016-08-02

Phase 2

DAR-901 TB Booster Vaccine to Prevent TB in Adolescents

CompletedNCT02712424

Dartmouth-Hitchcock Medical CenterTuberculosis

Start: 2016-03-31End: 2020-02-01Updated: 2021-05-11

Related Papers

DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial.

2020-09-2942 citations

The potential of CBC-derived ratios (monocyte-to-lymphocyte, neutrophil-to-lymphocyte, and platelet-to-lymphocyte) to predict or diagnose incident TB infection in Tanzanian adolescents

BMC Infectious Diseases2020-08-1818 citations

CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial

PLoS ONE2019-05-2322 citations

Altruism, Scepticism, and collective decision-making in foreign-born U.S. residents in a tuberculosis vaccine trial

BMC Public Health2018-04-2315 citations

Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901

PLoS ONE2017-05-1274 citations